Recruiting
Registered drugNo placebo
Study on the Safety and Effectiveness of Teclistamab and Talquetamab for Patients with Newly Diagnosed Multiple Myeloma Eligible for Transplant
Registered drugNo placebo
- Participants:Adults
JNJ-79635322
- 1 / 1
- trials open to patients / all trials
- 1+
- Countries
About the substance
Table of contents
- What is JNJ-79635322?
- How does JNJ-79635322 work?
- Which conditions is JNJ-79635322 being studied for?
- How is JNJ-79635322 given?
- What do the clinical trials show?
- What side effects are known?
What is JNJ-79635322?
JNJ-79635322 is an investigational antibody. It is not yet authorised as a medicine. In the EU Clinical Trials Information System, the substance is studied in oncology, specifically in multiple myeloma.[1] The development code JNJ-79635322 is the only name used for this substance in the available trial record.
How does JNJ-79635322 work?
The available registry record does not describe the mechanism of action of JNJ-79635322. It is being studied together with other antibody medicines, teclistamab and talquetamab, in combination regimens for multiple myeloma.[1]
Which conditions is JNJ-79635322 being studied for?
- Newly diagnosed multiple myeloma in people who are eligible for stem cell transplantation. This is a cancer of plasma cells in the bone marrow, and the trial studies JNJ-79635322 as part of combination treatment from the start of therapy.[1]
How is JNJ-79635322 given?
JNJ-79635322 is given as a subcutaneous injection, which means it is injected under the skin. The trial record lists a 1 mg dose for JNJ-79635322.[1]
What do the clinical trials show?
One Phase 2 trial is authorised for JNJ-79635322. It is an interventional study that plans to enrol 130 participants with newly diagnosed multiple myeloma who are eligible for stem cell transplantation.[1] The trial studies JNJ-79635322 in combination with other medicines, including teclistamab and talquetamab, which are also antibodies.[1]
The primary endpoint is the incidence and severity of adverse events and serious adverse events during treatment. This means the main question is how safe and tolerable the combination regimens are.[1]
The trial includes several medicines as part of the combination regimens: JNJ-64407564, teclistamab, daratumumab, lenalidomide, bortezomib and dexamethasone. Lenalidomide is taken orally, while JNJ-79635322, JNJ-64407564, teclistamab and daratumumab are given subcutaneously.[1]
What side effects are known?
The available registry record does not report side effects for JNJ-79635322. The trial itself is designed to measure the incidence and severity of adverse events and serious adverse events, so safety information will come from this study.[1]
Conditions where JNJ-79635322 is being studied
Each condition opens its own overview and trial list
Trials with JNJ-79635322
Recruiting trials first
Quick filters